← Back to home

Subclinical acute antibody-mediated rejection in kidney transplantation

Clinical trials for Subclinical acute antibody-mediated rejection in kidney transplantation explained in plain language.

Never miss a new study

Get alerted when new Subclinical acute antibody-mediated rejection in kidney transplantation trials appear

Sign up with your email to follow new studies for Subclinical acute antibody-mediated rejection in kidney transplantation, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

Kidney transplant rejection trial pulled before it began

Disease control Cancelled

This study was designed to test whether the drug eculizumab could treat early, symptom-free antibody-mediated rejection in kidney transplant recipients. The goal was to prevent long-term damage and chronic rejection. However, the trial was withdrawn before enrolling any participa…

Matched conditions: SUBCLINICAL ACUTE ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANTATION

Phase 1/2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control

Last updated Jun 27, 2026 07:58 UTC

Subclinical acute antibody-mediated rejection in kidney transplantation

Get alerted when new Subclinical acute antibody-mediated rejection in kidney transplantation trials appear

Kidney transplant rejection trial pulled before it began